Occurrence of Fibrin and Tissue Factor Antigen in Human Small Cell Carcinoma of the Lung 1

Cancer Research

Volumn 43, Issue 8, 1983, Pages 3963-3968

  Zacharski, Leo R ^a   Schned, Alan R ^a   Sorenson, George D ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN;

BLOOD CLOTTING; CYTOLOGY; ELECTRON MICROSCOPY; HUMAN; IMMUNOFLUORESCENCE; LUNG CANCER; RESPIRATORY SYSTEM; SMALL CELL CARCINOMA;

ANTIGENS; CARCINOMA, SMALL CELL; FIBRIN; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; LUNG NEOPLASMS; MICROSCOPY, ELECTRON; SUPPORT, U.S. GOV'T, NON-P.H.S.; THROMBOPLASTIN;

EID: 0020526129     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Brugarolas, A., Elias, E. G., Takita, H., Mink, I. B., Mittelman, A., and Ambrus, J. L. Blood coagulation and fibrinolysis in patients with carcinoma of the lung. J. Med. (Westbury), 4: 96-105, 1973.
2. Byrd, R. B., Divertie, M. B., and Spittell, J. A., Jr. Bronchogenic carcinoma and thromboembolic disease. J. Am. Med. Assoc., 202: 1019-1022, 1967.
3. Dano, K., and Reich, E. Serine enzymes released by cultured neoplastic cells. J. Exp. Med., 147: 745-757, 1978.
4. Dvorak, H. F., Dickersin, G. R., Dvorak, A. M., Manseau, E. J., and Pyne, K. Human breast carcinoma: Fibrin deposits and desmoplasia. Inflammatory cell type and distribution. Microvasculature and infarction. J. Natl. Cancer Inst., 67: 335-345, 1981.
5. Dvorak, H. F., Orenstein, N. S., and Dvorak, A. M. Tumor-secreted mediators and the tumor microenvironment: Relationship to immunologic surveillance. Lymphokines, 2: 203-233, 1981.
6. Edwards, R. L., Rickles, F. R., and Cronlund, M. Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation. J. Lab. Clin. Med., 98: 917-928, 1981.
7. Faulk, W. P., and Johnson, P. M. Immunological studies of human placentae: Identification and distribution of proteins in mature chorionic villi. Clin. Exp. Immunol., 27: 365-375, 1977.
8. Forman, W. G., and Barnhart, M. I. Cellular site for fibrinogen synthesis. J. Am. Med. Assoc., 187: 128-132, 1964.
9. Gamer, D. L., Reamer, S. A., Johnson, L. A., and Lessley, B. A. Failure of immunoperoxidase staining to detect acrosin in the equatorial segment of spermatozoa. J. Exp. Zool., 201: 309-315, 1977.
10. Gau, G. S., and Ryder, T. A. New vistas in histopathoiogy. Lancet, 2: 1005, 1978.
11. Gralnick, H. R. Cancer cell procoagulant activity. In: M. B. Donati, J. F. Davidson, and S. Garattini (eds.), Malignancy and the Hemostatic System, pp. 57–63. New York: Raven Press, 1981.
12. Hagedom, A. B., Bowie, E. J. W., Elvebach, L. R., and Owen, C. A., Jr. Coagulation abnormalities in patients with inoperable lung cancer. Mayo Clin. Proc., 49: 647-653, 1974.
13. Harris, N. L., Dvorak, A. M., Smith, J., and Dvorak, H. F. Fibrin deposits in Hodgkin's disease. Am. J. Pathol., 108: 119-129, 1982.
14. Loachim, H. L., Dorsett, B. H., and Paluch, E. The immune response at the tumor site in lung carcinoma. Cancer (Phila.), 38: 2296-2309, 1976.
15. Karpatkin, S., and Pearlstein, E. Role of platelets in tumor cell metastasis. Ann. Intern. Med., 95: 636-641, 1981.
16. Markus, G., Takita, H., Camiolo, S. M., Corasanti, J. G., Evers, J. L., and Hobika, G. H. Content and characterization of plasminogen activators in human lung tumors and normal lung tissue. Cancer Res., 40: 841-848, 1980.
17. Peuscher, F. W., Cleton, F. J., Armstrong, L., Stoepman-Van Dalen, E. A., Van Meurik, J. A., and Van Aken, W. G. Significance of plasma fibrino-peptide A (fpA) in patients with malignancy. J. Lab. Clin. Med., 96: 5-14, 1980.
18. Poggi, A., Colucci, M., Delaini, F., Semeraro, N., and Donati, M. B. Reduced procoagulant activity of Lewis lung carcinoma cells from mice treated with warfarin. Eur. J. Cancer, 16: 1641-1642, 1980.
19. Ranchod, M. The histogenesis and development of pulmonary tumorlets. Cancer (Phila.), 39: 1135-1145, 1977.
20. Schaeffer, J. R. Interference in localization of I131 fibrinogen in rat tumors by anticoagulants. Am. J. Physiol., 206: 573-579, 1964.
21. Semeraro, N., and Donati, M. B. Pathways of blood clotting initiation by cancer cells. In: M. B. Donati, J. F. Davidson, and S. Garattini (eds.), Malignancy and the Hemostatic System, pp. 65–81. New York: Raven Press, 1981.
22. Wamke, R., Pederson, M., Williams, C., and Levy, R. A study of lymphopro-liferative diseases comparing immunofluorescence with immunohistochemistry. Am. J. Clin. Pathol., 70: 867-875, 1978.
23. Yoda, Y., and Abe, T. Fibrinopeptide A (FPA) level and fibrinogen kinetics in patients with malignant disease. Thromb. Haemostasis, 4: 706-709, 1981.
24. Yuen, P., Kwaan, H. C., and Ho, F. Fibrinolysis in solid tumors. Thromb. Haemostasis. 42: 30, 1979.
25. Zacharski, L R., Henderson, W. G., Rickles, F. R., Forman, W. B., Cornell, C. J., Jr., Forcier, R. J., Edwards, R., Headley E., Kim, S-H., O'Donnell, J. R., O'Dell, R., Tomyos, K., and Kwaan, H. C. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Cooperative Study No. 75. J. Am. Med. Assoc., 245: 831-835, 1981.
26. Zacharski, L. R., Henderson, W. G., Rickies, F. R., Forman, W. B., Cornell, C. J., Jr., Forcier, R. J., Harrower, M. W., and Johnson, R. O. Rationale and experimental design for the VA cooperative study of anti-coagulation (warfarin) in the treatment of cancer. Cancer (Phila.), 44: 732-741, 1979.
27. Zacharski, L. R., Rickles, F. R., Henderson. W. G., Martin, J. F., Forman, W. G., Van Eeckhout, J. P., Cornell. C. J., and Forcier, R. J. Platelets and malignancy: Rationale and experimental design for the VA cooperative study of RA-233 in the treatment of cancer. Am. J. Clin. Oncol., 5: 593-609, 1983.
28. Zacharski, L. R., Rosenstein, R., and Philips, P. G. Tissue factor, a vitamin K-dependent clotting factor? Ann. N. Y. Acad. Sci., 370: 311-324, 1980.